352 related articles for article (PubMed ID: 20505188)
1. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.
Yang G; Rosen DG; Liu G; Yang F; Guo X; Xiao X; Xue F; Mercado-Uribe I; Huang J; Lin SH; Mills GB; Liu J
Clin Cancer Res; 2010 Aug; 16(15):3875-86. PubMed ID: 20505188
[TBL] [Abstract][Full Text] [Related]
2. Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer.
Shao H; Mohamed EM; Xu GG; Waters M; Jing K; Ma Y; Zhang Y; Spiegel S; Idowu MO; Fang X
Oncotarget; 2016 Jan; 7(4):3832-46. PubMed ID: 26716645
[TBL] [Abstract][Full Text] [Related]
3. NFATc1 regulates cell proliferation, migration, and invasion of ovarian cancer SKOV3 cells in vitro and in vivo.
Li L; Duan Z; Yu J; Dang HX
Oncol Rep; 2016 Aug; 36(2):918-28. PubMed ID: 27350254
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.
Xiao X; Yang G; Bai P; Gui S; Nyuyen TM; Mercado-Uribe I; Yang M; Zou J; Li Q; Xiao J; Chang B; Liu G; Wang H; Liu J
BMC Cancer; 2016 Aug; 16():582. PubMed ID: 27484466
[TBL] [Abstract][Full Text] [Related]
5. Paris saponin II inhibits human ovarian cancer cell-induced angiogenesis by modulating NF-κB signaling.
Yang M; Zou J; Zhu H; Liu S; Wang H; Bai P; Xiao X
Oncol Rep; 2015 May; 33(5):2190-8. PubMed ID: 25760800
[TBL] [Abstract][Full Text] [Related]
6. NF-κB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression.
Ignacio RM; Kabir SM; Lee ES; Adunyah SE; Son DS
PLoS One; 2016; 11(10):e0164189. PubMed ID: 27723802
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
[TBL] [Abstract][Full Text] [Related]
8. A key role for early growth response-1 and nuclear factor-kappaB in mediating and maintaining GRO/CXCR2 proliferative signaling in esophageal cancer.
Wang B; Khachigian LM; Esau L; Birrer MJ; Zhao X; Parker MI; Hendricks DT
Mol Cancer Res; 2009 May; 7(5):755-64. PubMed ID: 19435811
[TBL] [Abstract][Full Text] [Related]
9. Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy.
Agarwal A; Tressel SL; Kaimal R; Balla M; Lam FH; Covic L; Kuliopulos A
Cancer Res; 2010 Jul; 70(14):5880-90. PubMed ID: 20570895
[TBL] [Abstract][Full Text] [Related]
10. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis.
Takahashi Y; Koyanagi T; Suzuki Y; Saga Y; Kanomata N; Moriya T; Suzuki M; Sato Y
Mol Cancer Res; 2012 Sep; 10(9):1135-46. PubMed ID: 22826464
[TBL] [Abstract][Full Text] [Related]
11. CXCR2-driven ovarian cancer progression involves upregulation of proinflammatory chemokines by potentiating NF-κB activation via EGFR-transactivated Akt signaling.
Dong YL; Kabir SM; Lee ES; Son DS
PLoS One; 2013; 8(12):e83789. PubMed ID: 24376747
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis.
Li J; Cheng Y; Tai D; Martinka M; Welch DR; Li G
Oncogene; 2011 Feb; 30(8):896-906. PubMed ID: 20935672
[TBL] [Abstract][Full Text] [Related]
13. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis.
Fang Y; Li Z; Wang X; Zhang S
Tumour Biol; 2012 Dec; 33(6):2299-306. PubMed ID: 22923389
[TBL] [Abstract][Full Text] [Related]
14. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.
Zaid TM; Yeung TL; Thompson MS; Leung CS; Harding T; Co NN; Schmandt RS; Kwan SY; Rodriguez-Aguay C; Lopez-Berestein G; Sood AK; Wong KK; Birrer MJ; Mok SC
Clin Cancer Res; 2013 Feb; 19(4):809-20. PubMed ID: 23344261
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle-related kinase supports ovarian carcinoma cell proliferation via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma.
Wu GQ; Xie D; Yang GF; Liao YJ; Mai SJ; Deng HX; Sze J; Guan XY; Zeng YX; Lin MC; Kung HF
Int J Cancer; 2009 Dec; 125(11):2631-42. PubMed ID: 19672860
[TBL] [Abstract][Full Text] [Related]
16. GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade.
Yung MM; Tang HW; Cai PC; Leung TH; Ngu SF; Chan KK; Xu D; Yang H; Ngan HY; Chan DW
Theranostics; 2018; 8(5):1270-1285. PubMed ID: 29507619
[TBL] [Abstract][Full Text] [Related]
17. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
18. Volatile anaesthetics enhance the metastasis related cellular signalling including CXCR2 of ovarian cancer cells.
Iwasaki M; Zhao H; Jaffer T; Unwith S; Benzonana L; Lian Q; Sakamoto A; Ma D
Oncotarget; 2016 May; 7(18):26042-56. PubMed ID: 27028996
[TBL] [Abstract][Full Text] [Related]
19. Efficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels.
Yang F; Gou M; Deng H; Yi T; Zhong Q; Wei Y; Zhao X
Oncol Rep; 2012 Aug; 28(2):668-76. PubMed ID: 22684947
[TBL] [Abstract][Full Text] [Related]
20. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]